Wall Street analysts expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings of $1.28 per share for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Alexion Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $1.11 and the highest estimate coming in at $1.53. Alexion Pharmaceuticals posted earnings per share of $1.26 in the same quarter last year, which would indicate a positive year over year growth rate of 1.6%. The company is expected to announce its next quarterly earnings report on Thursday, February 15th.

On average, analysts expect that Alexion Pharmaceuticals will report full year earnings of $5.67 per share for the current fiscal year, with EPS estimates ranging from $5.50 to $5.90. For the next financial year, analysts expect that the company will post earnings of $7.09 per share, with EPS estimates ranging from $6.50 to $8.64. Zacks’ EPS calculations are an average based on a survey of research firms that follow Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. During the same quarter last year, the company posted $1.23 EPS. The firm’s revenue was up 7.5% compared to the same quarter last year.

Several equities analysts have commented on ALXN shares. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. TheStreet cut shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Royal Bank Of Canada raised their price target on shares of Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Piper Jaffray Companies reissued an “overweight” rating and issued a $170.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Finally, Stifel Nicolaus decreased their price objective on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a research report on Tuesday, October 24th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $154.49.

Shares of Alexion Pharmaceuticals (ALXN) traded up $7.68 during mid-day trading on Friday, reaching $114.46. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $149.34. The firm has a market capitalization of $25,570.00, a price-to-earnings ratio of 23.41, a P/E/G ratio of 1.24 and a beta of 1.18.

A number of large investors have recently made changes to their positions in ALXN. Steward Partners Investment Advisory LLC purchased a new stake in Alexion Pharmaceuticals during the 3rd quarter valued at about $274,000. GSA Capital Partners LLP boosted its holdings in Alexion Pharmaceuticals by 63.0% during the 3rd quarter. GSA Capital Partners LLP now owns 3,836 shares of the biopharmaceutical company’s stock valued at $538,000 after acquiring an additional 1,482 shares during the period. IFM Investors Pty Ltd purchased a new stake in Alexion Pharmaceuticals during the 3rd quarter valued at about $878,000. Fieldpoint Private Securities LLC boosted its holdings in Alexion Pharmaceuticals by 167.5% during the 3rd quarter. Fieldpoint Private Securities LLC now owns 1,792 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 1,122 shares during the period. Finally, Sterling Capital Management LLC purchased a new stake in Alexion Pharmaceuticals during the 3rd quarter valued at about $306,000. Hedge funds and other institutional investors own 94.16% of the company’s stock.

WARNING: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/alexion-pharmaceuticals-inc-alxn-expected-to-announce-earnings-of-1-28-per-share/1756402.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.